Leerink Partnrs Has Negative Estimate for Zoetis Q4 Earnings

Zoetis Inc. (NYSE:ZTS) – Analysts at Leerink Partnrs cut their Q4 2025 earnings per share estimates for shares of Zoetis in a note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $1.38 for the quarter, down from their prior estimate of $1.44. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis’ FY2026 earnings at $6.74 EPS, FY2027 earnings at $7.21 EPS and FY2028 earnings at $7.69 EPS.

A number of other equities research analysts have also recently commented on ZTS. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis in a research note on Tuesday. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, UBS Group lowered their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $191.00.

Zoetis Trading Up 0.5%

Shares of NYSE:ZTS opened at $120.20 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis has a 12-month low of $117.26 and a 12-month high of $181.85. The business has a 50 day moving average of $144.21 and a two-hundred day moving average of $152.60. The company has a market capitalization of $53.27 billion, a PE ratio of 20.69, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the company earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Zoetis by 11.3% in the first quarter. DekaBank Deutsche Girozentrale now owns 370,422 shares of the company’s stock worth $60,174,000 after acquiring an additional 37,544 shares during the last quarter. Flossbach Von Storch SE acquired a new stake in shares of Zoetis in the first quarter worth approximately $292,000. Greenleaf Trust increased its position in shares of Zoetis by 16.7% during the first quarter. Greenleaf Trust now owns 9,689 shares of the company’s stock worth $1,595,000 after purchasing an additional 1,386 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.